NASDAQ : BFRI
Biofrontera Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.9315 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 12.92M |
| Enterprise Value | 15.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.85M |
| Shares Outstanding | 14.85M |
| Shares Change (YoY) | +49.16% |
| Shares Change (QoQ) | +10.62% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 12.40% |
| Float | 11.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 5.48 |
| PS Ratio | 0.28 |
| Forward PS | 0.28 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 3.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.18 |
| Quick Ratio | 1.00 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.78 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -988.35% |
| Return on Assets (ROA) | -17.45% |
| Return on Invested Capital (ROIC) | -55.91% |
| Return on Capital Employed (ROCE) | -45.63% |
| Weighted Average Cost of Capital (WACC) | 7.60% |
| Revenue Per Employee | $491,223 |
| Profits Per Employee | -$67,713 |
| Employee Count | 94 |
| Asset Turnover | 2.09 |
| Inventory Turnover | 3.74 |
Taxes
| Measure | Value |
|---|
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -17.65% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 42.42 |
| Average Volume (20 Days) | 230,871 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 103,148 |
| Short Previous Month | 146,851 |
| Short % of Shares Out | 0.69% |
| Short % of Float | 0.87% |
| Short Ratio (days to cover) | 0.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 46.18M |
| Gross Profit | 36.60M |
| Operating Income | -6.17M |
| Pretax Income | -6.34M |
| Net Income | -6.37M |
| EBITDA | -5.97M |
| EBIT | -6.17M |
| Loss Per Share | -$0.54 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.67M |
| Total Debt | 7.50M |
| Net Cash | -2.84M |
| Net Cash Per Share | -$0.19 |
| Equity (Book Value) | 5.96M |
| Book Value Per Share | 0.42 |
| Working Capital | 1.89M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.93M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 203,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.93M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 79.25% |
| Operating Margin | -13.36% |
| Pretax Margin | -13.72% |
| Profit Margin | -13.78% |
| EBITDA Margin | -12.92% |
| EBIT Margin | -13.36% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.16% |
| Shareholder Yield | -49.16% |
| Earnings Yield | -62.15% |
| FCF Yield | -61.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.00 |
| Price Target Difference | 589.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 17.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.24 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |